Cardiovascular Systems Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Jun 30, 2022	FY2021 12 months to Jun 30, 2021	FY2020 12 months to Jun 30, 2020	FY2019 12 months to Jun 30, 2019	FY2018 12 months to Jun 30, 2018
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of property and equipment
Provision for (recovery of) doubtful accounts (including note receivable)
Amortization of intangible assets
Charges incurred in connection with acquired IPR&D
Provision for doubtful accounts
Financing Receivable, Allowance for Credit Loss, Recovery
Write-off of patent costs
Stock-based compensation
Other
Accretion (Amortization) of Discounts and Premiums, Investments

Other
Changes in assets and liabilities
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenue
Net cash used in operating activities
Cash flows from investing activities
Expenditures for property and equipment
Purchase of investment
Proceeds from (issuance of) convertible note receivable
Acquisitions
Purchases of long-term investments
Purchases of marketable securities
Sales of marketable securities
Maturities of marketable securities
Costs incurred in connection with patents
Proceeds from convertible note receivable
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from the employee stock purchase plan
Payment of employee taxes related to vested restricted stock
Exercise of stock options
Proceeds from financing
Proceeds from offering of common stock
Principal payments made on financing obligation
Net cash (used in) provided by financing activities

Net change in cash and cash equivalents
Cash and cash equivalents
Beginning of period
End of period
Change in equipment included in accounts payable
Change in patent costs included in accounts payable
Beginning of period
End of period
Supplemental cash flow information
Interest paid

Comments